Slide 1: Azelis Lab Tour 2025
Azelis Lab Tour 2025 Hertford, UK Tuesday, 16 September 2025
Slide 2: Agenda
Agenda Reception & lunch Management presentation Lab tour and digital workshop Wrap-up and farewell 2
Slide 3: Meet Anna Bertona, Group CEO
Meet Anna Bertona Group CEO I. Industry overview II. Azelis’s strategy III. Snapshot on progress 3
Slide 4: Fully integrated innovation solutions provider
Fully integrated innovation solutions provider Value for customers Value for principals • Tailored support, from concept to launch • Strategic alignment with a growth- • Local technical sales teams with market driven partner know-how • Trust-based, long-term collaboration • Digital and face-to-face
Slide 5: Fundamentals are intact and megatrends driving the industry are unchanged
Fundamentals are intact and megatrends driving the industry are unchanged Volatility is here EU-based chemical Increasing regulatory New technology and AI Evolving Global to stay producers face pressure & sustainability changing the way we Workforce challenges requirements do business • Trade & tari
Slide 6: The market for speciality chemical distribution and food ingredients remains attractive
The market for speciality chemical distribution and food ingredients remains attractive Growth Resilience Consolidation Scale Fragmented industry, Speciality chemical Diversified resilient with still few large global Large global players are 1. 2. 3. 4. distribution is large and end-markets with a n
Slide 7: Strategy focused on long-term value-creation and successful navigation of near-term challenges
Strategy focused on long-term value-creation and successful navigation of near-term challenges Innovation through formulation. We are driven by innovation. Through the application of science, we act as catalysts for innovations that positively impact people, communities, and our planet for a more su
Slide 8: Valuing, recognising and driving innovation
Valuing, recognising and driving innovation Combining products … Azelis leverages its 70+ labs to create and ... to support our joint customers throughout the from multiple principals… enhance both new and existing formulations … product development process until commercial launch. Award-winning The
Slide 9: At the forefront of digital transformation
Horizon 3 ● Extend our position as the digital category definer ● Turn data into business At the forefront Horizon 2 insights (analytics, data interpretation) of digital ● Develop digital journey for ● Turn insights into actions (AI-based cross-selling, transformation customers, from inspiration to
Slide 10: Meet Thijs Bakker, Group CFO
Meet Thijs Bakker Group CFO I. Financial performance track record II. Profitability III. Asset-light, resilient business model 10 Azelis Lab Tour 2025 | 16 September 2025
Slide 11: Excellent financial track record through the cycle at group level
Excellent financial track record through the cycle at group level… Revenue1 (€m) Conversion margin2 Organic growth (%) Life Sciences Industrial Chemicals 50% 48% 47% 2.0 0.2 15.7 20.1 (5.9) (1.1) 48% 46% 46% +1% +1% 44% +45% 41% +10% +6% +27% 42% 4.109 4.152 4.214 40% 39% 2.827 1.635 1.587 1.561 38%
Slide 12: Expanding portfolio density drives margin improvement
Expanding portfolio density drives margin improvement Multiple white spots in our footprint… …representing margin upside Life Sciences Industrial Chemicals Adj. EBITA Margin vs. Scale1 Azelis countries (2020) Segment 1 Segment 2 Segment 3 Segment 4 Segment 5 Segment 6 Segment 7 Segment 8 Segment 9 S
Slide 13: Asset light and highly cash generative business
Asset light and highly cash generative business 601 Proven track record of free cash flow generation on the back of: 438 o Low Capex requirements reflecting its 342 asset-light business model (< 0.5% of Free cash flow1 revenue) (€m) 188 o Continuous improvement in working 182 128 137 capital efficie
Slide 14: Highly flexible cost base adds further resilience to the business model
Highly flexible cost base adds further resilience to the business model Cost structure overview Illustrative cost base below gross profit Others5 €m 2023A 2024A T&E costs4 Total income 4,176 4,238 Fixed costs Costs for goods and consumables (1) (3,192) (3,207) Variable Utilities, Gross profit 984 1,
Slide 15: Meet Charles Hawley, Managing Director UK
Meet Charles Hawley Managing Director UK 15
Slide 16: Azelis UK & Ireland offers a wide product portfolio
Azelis UK & Ireland offers a Azelis history in wide product portfolio UK and Ireland 2017 Azelis develops the Balance across segments reflects UK and Key milestones and award-winning Ireland local manufacturing activities growth timeline MASKerade biodegradable sheet mask at Hertford labs. 2018 Azel
Slide 17: Appendix
Appendix
Slide 18: Our future focus builds on our current broad platform
Our future focus builds on our current broad platform, leading to a resilient model, geared for growth In the past In the future Global footprint with • In-market and in-region expansion to reinforce the portfolio Geography Strong footprint in • Footprint to include fast-growing regions and ‘difficu
Slide 19: An active consolidator driving growth in three areas
Growing with Growing with Growing through customers principals M&A An active + + consolidator Increased sales by our Mandate wins to M&A in key countries and driving growth in sales teams to grow our footprint with existing continuously develop our business and improve market segments to strategical
Slide 20: We are one agile Azelis
We are one agile Azelis Empowered organisation With shared focus Lean corporate and regional offices. One shared strategy with aligned and consistent objectives Flat organisational structure with clear roles and responsibilities. Standardised systems and processes Accountability at all levels, Centr